The ABLIM3 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ABLIM3 gene in the Huh-7 human hepatocellular carcinoma cell line. This loss-of-function model enables researchers to investigate the role of ABLIM3 in actin cytoskeleton organization and cell adhesion without the use of clonal selection, preserving population-level heterogeneity that may better reflect tumor biology. The polyclonal knockout format is generated through targeted gene disruption using CRISPR/Cas9, resulting in a heterogeneous pool of cells carrying diverse ABLIM3 mutations, which is suitable for functional studies where gene inactivation rather than a defined genetic alteration is the primary objective.
The Huh-7 cell line, originally derived from a liver tumor of a 57-year-old Japanese male, is a widely employed model for hepatitis C virus research and hepatocellular carcinoma biology. These cells are epithelial and tumorigenic, retaining key features of liver cancer such as anchorage-independent growth and invasive capacity. Their robust growth and well-characterized signaling pathways make Huh-7 cells an ideal platform for studying the molecular mechanisms of liver carcinogenesis and metastatic progression.
ABLIM3 encodes a protein that directly binds filamentous actin (F-actin) through its villin headpiece domain and LIM domains, linking the actin cytoskeleton to focal adhesion complexes. ABLIM3 is regulated by Rho GTPases including RhoA, Rac1, and CDC42, and functions upstream of F-actin polymerization and focal adhesion dynamics. It interacts with other LIM domain proteins and integrin-associated proteins, and is a key component of the focal adhesion pathway alongside integrins, focal adhesion kinase (FAK), and paxillin. In hepatocellular carcinoma, ABLIM3 is hypothesized to modulate cytoskeletal reorganization and cell migration, processes that are critical for tumor invasion and metastasis.
In the Huh-7 hepatocellular carcinoma context, ABLIM3 knockout likely disrupts actin filament architecture and focal adhesion turnover, impairing normal cell adhesion and altering migratory behavior. Given the role of the actin cytoskeleton in cancer cell motility, this knockout model provides a valuable tool for dissecting the signaling networks that drive liver cancer invasion. The interplay between ABLIM3 and the Hippo signaling pathway, as well as mechanical tension sensing, may further illuminate how tumor cells adapt their cytoskeletal dynamics to promote metastatic dissemination.
Researchers can employ these ABLIM3 knockout cells in a variety of assays including western blotting for ABLIM3 and actin-binding proteins, immunofluorescence staining of F-actin to visualize cytoskeletal changes, and Transwell migration and invasion assays to assess metastatic potential. Additional applications include quantitative real-time PCR to profile gene expression changes, co-immunoprecipitation of actin-ABLIM3 complexes, and live-cell imaging of cytoskeletal dynamics. This model is instrumental for drug target discovery and preclinical evaluation of therapeutic strategies aimed at halting liver cancer metastasis. For further information, please contact Ascent Research.
